Leukemia Research
Volume 28, Issue 3 , Pages 259-266 , March 2004

Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival

  • M.G Alexandrakis

      Affiliations

    • Division of Medicine, University Hospital of Heraklion, Medical School of Crete, P.O. Box 1352, Crete, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30-2810-392425; fax: +30-2810-244883.
    • ,
  • F.H Passam

      Affiliations

    • Third Department of Internal Medicine, Hematology Unit, Sotiria Hospital, Medical School of Athens, Athens, Greece
    • ,
  • K Sfiridaki

      Affiliations

    • Hematology Unit, Venizelion General Hospital of Heraklion, Crete, Greece
    • ,
  • J Moschandrea

      Affiliations

    • Department of Social & Environmental Medicine, Medical School of Crete, Crete, Greece
    • ,
  • C Pappa

      Affiliations

    • Department of Hematology, University Hospital of Heraklion, Medical School of Crete, Crete, Greece
    • ,
  • D Liapi

      Affiliations

    • Hematology Unit, Venizelion General Hospital of Heraklion, Crete, Greece
    • ,
  • E Petreli

      Affiliations

    • Third Department of Internal Medicine, Hematology Unit, Sotiria Hospital, Medical School of Athens, Athens, Greece
    • ,
  • P Roussou

      Affiliations

    • Third Department of Internal Medicine, Hematology Unit, Sotiria Hospital, Medical School of Athens, Athens, Greece
    • ,
  • D.S Kyriakou

      Affiliations

    • Department of Hematology, University Hospital of Larisa, Medical School of Thessalia, Thessalia, Greece

Received 5 March 2003 ,Accepted 14 July 2003.

References 

  1. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura T, Tanimoto K, et al.  Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 1995;378:88–91
  2. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53–72
  3. Dinarello C. Interleukin-18. Methods. 1999;19:121–132
  4. Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J. Mol. Med. 2002;80:147–162
  5. Akira S. The role of IL-18 in innate immunity. Curr. Opin. Immunol. 2000;12:59–63
  6. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, et al.  Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J. Exp. Med. 1997;185:1005–1012
  7. Park C, Morel J, Asif Amin M, Connors M, Harlow L, Koch A. Evidence of IL-18 as a novel angiogenic mediator. J. Immunol. 2001;167:1644–1653
  8. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. North Am. 1992;6:273–284
  9. Vacca A, Ribatti D, Presta M, Minischetti M, Lurlaro M, Ria R, et al.  Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064–3073
  10. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in hematological malignancies. Br. J. Haematol. 2000;111:43–51
  11. Yamashita K, Iwasaki T, Tsujimura T, Sugihara A, Yamada N, Ueda H, et al.  Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in bone marrow. Oncol. Rep. 2002;9:1237–1244
  12. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842–854
  13. Papadaki H, Kyriakou D, Foundoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol. 1997;97:191–195
  14. Stylianou E, Bjerkeli V, Yndestad A, Heggelund L, Waehre T, Damas JK, et al.  Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1 infected patients. Clin. Exp. Immunol. 2003;132:462–466
  15. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;13(Suppl 2):56–63
  16. Merendino RA, Gangemi S, Ruello A, Bene A, Losi E, Lonbardo G, et al.  Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int. J. Biol. Markers. 2001;16:126–129
  17. Park H, Byun D, Kim TS, Kim YI, Kang JS, Hahm ES, et al.  Enhanced IL-18 expression in common skin tumors. Immunol. Lett. 2001;79:215–219
  18. Liu Y, Huang H, Saxena A, Xiang J. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther. 2002;9:533–542
  19. Jonak ZL, Trulli S, Maier C, McCabe FL, Kirkpatrick R, Johanson K, et al.  High dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma. J. Immunother. 2002;25(Suppl 1):S20–S27
  20. Xiang J, Chen Z, Huang H, Moyana T. Regression of engineered myeloma cells, secreting interferon-g-inducing factor is mediated by both CD4+/CD8+ T and natural killer cells. Leukemia Res. 2001;25:909–915
  21. Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 1999;13:2195–2202
  22. Coughlin CM, Salhany KE, Wysocka M, et al.  Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 1998;101:1441–1452
  23. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through the inhibition of tumor vessel formation. J. Invest. Dermatol. 2002;119:541–548
  24. Vidal-Vanaclocha F, Fantuzzi G, Mendozaa L, et al.  IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. U.S.A. 2000;97:734–739
  25. Robak E, Wozniacka A, Jedrzejowska S, Stephien H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus. 2002;11:348–355
  26. Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al.  Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann. Hematol. 2000;79:574–577
  27. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumour expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003;63:3121–3126
  28. Netea MG, Kullberg BJ, Verschueren I, van Der Meer JW. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Eur. J. Immunol. 2000;30:3057–3060
  29. Ogura T, Ueda H, Hosohara K, Tsuji R, Nagata Y, Kashiwamura S, et al.  Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood. 2001;98:2101–2107
  30. Klein B, Zhang XE, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863–872
  31. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumor necrosis factor-a in multiple myeloma. Br. J. Haematol. 1990;74:424–431
  32. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C reactive protein and b2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733–737
  33. Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K. The clinical and prognostic significance of erythrocyte sedimantation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin. Lab. Haem. 2003;25:41–46

PII: S0145-2126(03)00261-3

doi: 10.1016/S0145-2126(03)00261-3

Leukemia Research
Volume 28, Issue 3 , Pages 259-266 , March 2004

Article Tools

* Image Usage & Resolution